IFNA1 and melanoma: IFNa and 5-Aza-2’-deoxycytidine combined with a DC targeting DNA vaccine (a MIP3a fused vaccine targeting two common melanoma antigens, gp100 and trp2) exhibited greater tumor infiltration of DCs, and NK cells, as well as reduced levels of MDSCs in vaccinated groups in the B16F10 melanoma model (173).